Hawaii Chapter - NBDF
Phone 808-284-7417

Our Mission

The National Bleeding Disorders Foundation (NBDF) Hawaii Chapter is dedicated to finding cures for inheritable blood disorders and addressing and preventing complications of these disorders through research, education, and advocacy enabling people and families to thrive.  

News Articles

The National Bleeding Disorders Foundation (NBDF) is delighted to announce a new accredited education opportunity for health care providers focused on personalized care for individuals with von Willebrand disease (VWD).

“Restoring Control in von Willebrand Disease: Collaborative Approaches for Delivering the Right Treatment for the Right Patient at the Right Time,” is an enduring activity planned and implemented by the PeerView Institute (PVI) for Medical Education and NBDF. 

The U.S. Food and Drug Administration (FDA) has approved the ConcizuTrace™ ELISA Companion Diagnostic (CDx) test, which helps to determine the amount of concizumab-mtci that is circulating in an individual who has taken the product.

In a May 27th letter to the hemophilia community, it was confirmed that Spark Therapeutics has been fully integrated into the Roche Group. Spark first became a member of the Roche Group in 2019 with the aim of continuing to advance potential gene therapies for hemophilia and many other genetic diseases.

View All

Resource Links

Hawaii Chapter - NBDF
75-5660 Kopiko Street, Suite C7 #294
Kailua-Kona, HI 96740
Phone 808-284-7417

© National Bleeding Disorders Foundation 2025

Crafted by Firespring